Malaysia Lung Cancer Therapeutics Market Analysis

Malaysia Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Malaysia Lung Cancer Therapeutics market will reach a value of $91 Mn from $48 Mn in 2022, growing at a CAGR of 8.3% during 2022-30.

Malaysia is a Southeast Asian country occupying parts of the Malay Peninsula and the island of Borneo. In Malaysia, healthcare services are divided into two systems: public and private. In Malaysia, the majority of patients (65%) seek health care services in public facilities. In Malaysia, smoking is common; about half of all adult males smoke, and more than 90 % of male lung cancer patients have a strong smoking history. In Malaysia, however, practically all young female lung cancer patients are non-smokers. National databases, such as the National Cancer Registry and the Malaysian Lung Cancer Registry, currently lack specific information on diagnostic and staging modalities, as well as treatment strategies employed in patients at various stages of the disease.

According to the latest WHO data published in 2020 Lung Cancers Deaths in Malaysia reached 4,319 or 2.57% of total deaths. The age-adjusted Death Rate is 15.25 per 100,000 population ranks Malaysia 77^th in the world. Malaysia's government spends 4.1% of its GDP on healthcare.

Market Dynamics

Market Growth Drivers

Lung cancer is one of the most frequent tumours in Malaysia, accounting for around 10% of all cancers. The lifetime risk for Malaysian males is around 1 in 55: the risk is highest among Chinese males (1 in 43), followed by Malays (1 in 62), and Indians residing in Malaysia. The majority of Malaysian lung cancer patients have locally progressed or metastatic disease, making curative surgical resection impossible. Malaysia has 36 oncology centres that offer radiotherapy and are equipped with 56 conventional megavoltage linear accelerators, three Gamma Knife devices, and one CyberKnife system. These aspects could boost Malaysia's Lung Cancer Therapeutics market.

Market Restraints

The primary disadvantage of public health care is the scarcity of doctors and experts in public hospitals. In Malaysia, about 90% of lung cancer patients are diagnosed with stage III or IV illness. A prominent tertiary public hospital reported a 4.8 % resection rate. The low rates could also be ascribed to a scarcity of thoracic surgeons (due to a strong cardiac surgical workload), patients' refusal of surgery, or prohibitive medical comorbidities.

Lung cancer awareness is still low, which contributes to most cases being diagnosed late. Additional barriers include the stigma of lung cancer as a "self-inflicted" disease, the dread of treatments such as chemotherapy and radiotherapy, and a cultural inclination toward alternative conventional and complementary medicines. In Malaysia, clinical trials for lung cancer treatment are scarce. These factors may deter new entrants into the Malaysia Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

• Pharmaniaga Berhad: Pharmaniaga Berhad is a Malaysian pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
• Hovid Berhad: Hovid Berhad is a Malaysian pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
• Duopharma Biotech Berhad: Duopharma Biotech Berhad is a Malaysian pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
• Biocon Sdn Bhd: Biocon Sdn Bhd is a Malaysian biotechnology company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
• Kotra Pharma: Kotra Pharma is a Malaysian pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer

Recent Notable Updates

September 2022: Cutting-edge Artificial Intelligence (AI) screening technology for lung cancer detection will soon be available to the public at three primary care clinics: Beacon Hospital, Subang Jaya Medical Centre, and Sunway Medical Centre. The Lung Cancer Network Malaysia (LCNM), AstraZeneca, and Qualitas Medical Group collaborated to create the free AI-lung cancer screening programme. Dr. Anand Sachithanandan, Cardiothoracic Surgeon and President of LCNM, launched the programme with Dr. Sanjeev Panchal, Country President, of AstraZeneca Malaysia, with the goal of closing the gap in early lung cancer detection.

Healthcare Policies and Reimbursement Scenarios

The regulation and reimbursement of lung cancer therapeutics in Malaysia are overseen by several entities, including the National Pharmaceutical Regulatory Agency (NPRA) and the Ministry of Health. To be eligible for reimbursement, lung cancer therapeutics must be included in the National Essential Medicine List (NEML), which is a list of drugs approved for reimbursement by the Ministry of Health. The MADRAC Bulletin features pharmacovigilance-related activities conducted by the National Pharmaceutical Regulatory Agency (NPRA) and contains a list of directives based on safety issues advised by the Malaysian Adverse Drug Reactions Advisory Committee (MADRAC) and endorsed by the Drug Control Authority (DCA) as well as safety alerts that have been published on the NPRA website.